Effects of IDH1 and IDH2 genes mutations on tumors

doi:10.3760/cma.j.issn.1673422X.2015.05.008

Abstract

Abstract: Isocitrate dehydrogenases (IDHs) are considered as key enzymes in the tricarboxylic acid cycle. Recurrent mutations in the IDH1 and IDH2 genes are recently found in several human cancers. Those point mutations specifically affect IDH1 and IDH2 active site arginine residues and confer a neomorphic enzyme function of directly catalyzing αketoglutarate (αKG) to R2hydroxyglutarate (R2HG). R2HG can competitively inhibits αKGdependent enzymes and may therefore contribute to the occurrence and development of tumor. In addition, Mutation status of IDH1 and IDH2 are closely relative to the progress and prognosis of certain tumor. Thus IDH1 and IDH2 are considered to be promising biomarkers for early diagnosis and prognosis and targeted therapy.

LIU Xiang, LING Zhi-Qiang. Effects of IDH1 and IDH2 genes mutations on tumors[J]. Journal of International Oncology, 2015, 42(5): 351-354.

References

［1］ Ye D, Ma S, Xiong Y, et al. R2hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis［J］. Cancer Cell， 2013, 23(3):274276. ［2］ Kim W, Liau LM. IDH mutations in human glioma［J］. Neurosurg Clin N Am， 2012, 23(3):471480. ［3］ Zhao S, Lin Y, Xu W, et al. Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF1alpha［J］. Science， 2009, 324(5924):261265. ［4］ Yang C, Fan J, Zhuang Z, et al. The role of NAD(+)dependent isocitrate dehydrogenase 3 subunit alpha in AFB1 induced liver lesion［J］. Toxicol Lett， 2014,224(3):3719. ［5］ Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme［J］. Science， 2008, 321(5897):18071812. ［6］ Dang L, White DW, Gross S, et al. Cancerassociated IDH1 mutations produce 2hydroxyglutarate［J］. Nature， 2010, 465(7300):966. ［7］ Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics［J］. Nature， 2012, 488(7413):656659. ［8］ Sasaki M, Knobbe CB, Itsumi M, et al. D2hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function［J］. Genes Dev， 2012, 26(18):20382049. ［9］ Zhang C, Moore LM, Li X, et al. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma［J］. Neuro Oncol， 2013, 15(9):11141126. ［10］ Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation［J］. Nature， 2012, 483(7390):474478. ［11］ Xu W, Yang H, Liu Y, et al. Oncometabolite 2hydroxyglutarate is a competitive inhibitor of alphaketoglutaratedependent dioxygenases［J］. Cancer cell， 2011, 19(1):1730. ［12］ Chowdhury R, Yeoh KK, Tian YM, et al. The oncometabolite 2hydroxyglutarate inhibits histone lysine demethylases［J］. EMBO Rep， 2011, 12(5):463469. ［13］ Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)2hydroxyglutarate, and cancer［J］. Genes Dev， 2013, 27(8):836852. ［14］ Figueroa ME, AbdelWahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation［J］. Cancer Cell， 2010, 18(6):553567. ［15］ Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma［J］. Cancer Cell， 2010, 17(5):510522. ［16］ Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype［J］. Nature， 2012, 483(7390):479483. ［17］ Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases［J］. Nat Rev Mol Cell Biol， 2012, 13(5):297311. ［18］ Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)enantiomer of 2hydroxyglutarate linked to EGLN activation［J］. Nature， 2012, 483(7390):484488. ［19］ Ward PS, Cross JR, Lu C, et al. Identification of additional IDH mutations associated with oncometabolite R()2hydroxyglutarate production［J］. Oncogene， 2012, 31(19):24912498. ［20］ Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas［J］. N Engl J Med， 2009, 360(8):765773. ［21］ Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas［J］. Am J Pathol， 2009, 174(4):11491153. ［22］ SongTao Q, Lei Y, Si G, et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma［J］. Cancer Sci， 2012, 103(2):269273. ［23］ Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in lowgrade gliomas［J］. Neurology， 2010, 75(17):15601566. ［24］ Bralten LB, Kloosterhof NK, Balvers R, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo［J］. Ann Neurol， 2011, 69(3):45563. ［25］ Rohle D, PopoviciMuller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells［J］. Science， 2013, 340(6132):626630. ［26］ Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation［J］. Science， 2013, 340(6132):622626. ［27］ Ledford H. Metabolic quirks yield tumour hope［J］. Nature， 2014, 508(7495):158159.